Survey to evaluate the effect of antiemetic therapy on dose intensity of EC/FEC or AC regimen as well as prognosis in patients with breast cancer (KBCSG1112)
Not Applicable
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000006284
- Lead Sponsor
- KBCSG (Kinki Breast Cancer Study Group)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 500
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percent of patients with 85% or more in relative dose intensity of epirubicin or doxorubicin
- Secondary Outcome Measures
Name Time Method